Lunai Bioworks Inc. (LNAI) Stock Score, Valuation & Financial Research

Lunai Bioworks Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for LNAI

Lunai Bioworks Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.23. These figures are a research snapshot, not a buy or sell recommendation.

What Lunai Bioworks Inc. does

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."

Company business and revenue

Research reporting period: 2025-06-30. A research update is not a new financial filing.

How the company makes money

Lunai Bioworks Inc. is a pre-revenue biotechnology company focused on the development of advanced cell, gene, and immunotherapy platforms for cancer and infectious diseases. The company generates no commercial revenue and relies on capital raises and financing activities to fund its research, development, and operational expenses.

Products and services

  • The company is developing therapeutic candidates including RenovaroGEM, a gene-modified cell therapy, and other preclinical assets focused on oncology and infectious disease treatments.

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes various unnamed third-party CROs to conduct preclinical and clinical studies. Source

Competitors and product-market comparisons

  • Biotechnology and pharmaceutical companies — The company competes with numerous established and emerging companies developing immunotherapies and cancer treatments. Source

Business strengths to evaluate

  • Proprietary technology platforms for cell and gene therapy Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

LNAI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.23
Market capitalization:
5.58M (currency not supplied)
Revenue:
USD 20.94K
Net income:
USD -128.28M
Free cash flow:
USD -7.87M
Cash:
USD 3.16M
Total debt:
USD 1.41M
EPS:
USD -61.25

What stands out

  • Free cash flow is USD -7.87M, negative for the stored period.
  • The balance sheet shows USD 3.16M of cash versus USD 1.41M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 1.74M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for LNAI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can LNAI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is LNAI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for LNAI to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of LNAI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-10.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research LNAI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.